{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:32:28Z","timestamp":1792099948134,"version":"4.4.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jaad.2016.09.006","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T11:31:02Z","timestamp":1478086262000},"page":"29-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["Tofacitinib for the treatment of alopecia areata and variants in adolescents"],"prefix":"10.1016","volume":"76","author":[{"given":"Brittany G.","family":"Craiglow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.09.006_bib1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2016.09.006_bib2","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.09.006_bib3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/jdv.13598","article-title":"Efficacy of tofacitinib in treatment of alopecia universalis in two patients","volume":"30","author":"Gupta","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.09.006_bib4","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/exd.13060","article-title":"Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers","volume":"25","author":"Jabbari","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2016.09.006_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2016.09.006_bib6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.09.006_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"issue":"15","key":"10.1016\/j.jaad.2016.09.006_bib8","first-page":"e89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2016.09.006_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: Results in 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.09.006_bib10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0190-9622(99)70195-7","article-title":"Alopecia areata\u00a0investigational assessment guidelines. National Alopecia Areata Foundation","volume":"40","author":"Olsen","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.09.006_bib11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","article-title":"Health-related quality of life (HRQoL) among patients with alopecia areata: a systematic review","volume":"75","author":"Liu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.09.006_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0010-440X(91)90045-E","article-title":"Lifetime prevalence of psychiatric disorders in patients with alopecia areata","volume":"32","author":"Colon","year":"1991","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.jaad.2016.09.006_bib13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1468-3083.2008.02956.x","article-title":"Alopecia areata prevalence by gender and age","volume":"23","author":"Kyriakis","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.09.006_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/1546-0096-13-S1-O31","article-title":"Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)","volume":"13","author":"Montealegre","year":"2015","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216307629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216307629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:40:52Z","timestamp":1759272052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216307629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0190962216307629"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.09.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726930316.793527887","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}